ClinicalTrials.gg
RecruitingNCT06103201Updated May 11, 2025

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

A Phase 1 interventional study of Hyperpolarized 13C-Pyruvate in Traumatic Brain Injury and Subarachnoid Hemorrhage, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by University of Maryland, Baltimore · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Brain Injuries, Traumatic by University of Maryland, Baltimore — 2 open to participants now, 2 under way, none of them phase 3. Brain Injuries, Traumatic · University of Maryland, Baltimore.

Started
2023
with 1 other
Phase 1
Only one
of the 11
Registered
10th of 11
by date

Among the 11 studies in Brain Injuries, Traumatic by University of Maryland, Baltimore, this one is one of 2 that started in 2023, is the only one in phase 1, and was the 10th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

2 of the 11 studies in Brain Injuries, Traumatic by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Brain Injuries, Traumatic by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI.

The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this study.

Up to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).

03

Conditions studied

  • Traumatic Brain Injury
  • Subarachnoid Hemorrhage
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of acute head injury with or suspected non-penetrating acute TBI
  • Suitable to undergo contrast-enhanced MRI
  • Negative serum pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Inability to undergo MRI scan
  • Inability to receive IV MRI contrast agents secondary to severe reaction or renal insufficiency
  • Positive pregnancy test
05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Metabolic MRI in traumatic brain injury patients

    Perform metabolic magnetic resonance imaging on patients who have traumatic brain injury to understand early brain metabolism changes in this population

    Drug: Hyperpolarized 13C-Pyruvate

  • Experimental
    Metabolic MRI in subarachnoid hemorrhage patients

    Perform metabolic magnetic resonance imaging on patients who have subarachnoid hemorrhage to understand early brain metabolism changes in this population

    Drug: Hyperpolarized 13C-Pyruvate

  • Experimental
    Metabolic MRI in healthy volunteers

    Perform metabolic magnetic resonance imaging on healthy volunteers to understand early brain metabolism changes in this population

    Drug: Hyperpolarized 13C-Pyruvate

Interventions

  • DrugHyperpolarized Carbon C 13 (1-13C) PyruvateStudies of Hyperpolarized Carbon C 13 (1-13C) PyruvateHyperpolarized Carbon C 13 (1-13C) Pyruvate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized ("hyperpolarized") \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury. Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].

06

What researchers measure

Primary outcomes

  1. Measures of conversion of pyruvate to lactate (apparent conversion rate constant kPL, lactate-to-pyruvate ratio) and pyruvate to bicarbonate (apparent conversion rate constant kPB, bicarbonate-to-pyruvate ratio)

    To assess the differences between the three patient groups

    Time frame: within two years post enrollment

Secondary outcomes

  1. Correlation of the conversion of pyruvate to lactate and pyruvate to bicarbonate measures with results from clinical and neuropsychological evaluation.

    Time frame: within two years post enrollment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2026, 37 months after the start.

Of 27 phase 1 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 66. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 26, 2023
StartActual
Oct 26, 2023
Primary completionEst.
Nov 26, 2026
CompletionEst.
Nov 26, 2027
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06103201
Responsible party
Jiachen Zhuo (Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Oct 26, 2023
Start date
Oct 26, 2023
Primary completion
Nov 26, 2026 (estimated)
Completion
Nov 26, 2027 (estimated)
Last update
May 11, 2025

Study contacts

Rosy Linda Njonkou Tchoquessi
Contact
rnjonkou@som.umaryland.edu
410-706-0943
Dirk Mayer, Dr. rer. nat.
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyperpolarized Carbon C 13 (1-13C) Pyruvate

Start the discussion